The role of Notch ligand, Delta-like ligand 4 (DLL4), in cancer angiogenesis—implications for therapy

Summary Background It is generally accepted that angiogenesis a complex and tightly regulated process characterized by the growth of blood vessels from existing vasculature. Activation Notch signalling pathway affects multiple aspects vascular development. One components pathway, Delta-like ligand 4 (DLL4), has recently appeared as critical regulator tumour thus promising therapeutic target. Methods This review article includes available data peer-reviewed publications associated with role DLL4 in cancer angiogenesis. Searches were performed PubMed, EMBASE, Google Scholar Web Science using terms “tumour angiogenesis”, “DLL4”, “Notch signalling” “anti-cancer therapy”. Results The survival curves patients revealed high expression levels had significantly shorter times than low expression. Moreover, positive correlation was also identified between VEGF receptorsʼ levels. seems inhibition may exert potent inhibitory effects on some tumours resistant to anti-VEGF therapies. A great number blocking agents DLL4/Notch including anti-DLL4 antibodies, DNA vaccination, antibodies gamma-secretase inhibitors have been studied preclinical models. Conclusion be target anti-cancer therapy. Nevertheless, careful evaluation adverse normal physiological processes relation doses drugs will significant for advancement clinical oncology.